Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.31 |
| ▸ | PPM1D | O15297 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30591392 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4PIM1CHRNB4CHRNA3 | |
| SCHEMBL3428965 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4PIM1CHRNB4CHRNA3 | |
| SCHEMBL18610000 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4PIM1CHRNB4CHRNA3 | |
| SCHEMBL17239764 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4PIM1CHRNB4CHRNA3 | |
| SCHEMBL18474094 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4PIM1CHRNB4CHRNA3 | |
| SCHEMBL31436224 | 0.85 | PIM2 (0.35) | PPM1D | |
| SCHEMBL4156977 | 0.84 | CYP2D6 (0.42) | PPM1D | |
| SCHEMBL5343341 | 0.84 | CYP2D6 (0.42) | PPM1D | |
| SCHEMBL15145321 | 0.84 | CYP2D6 (0.42) | PPM1D | |
| SCHEMBL14865098 | 0.84 | CYP2D6 (0.42) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2022-09-29 | — | — | US | disclosed |
| WO-2022197641-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-AMINE DERIVATIVES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS AND/OR INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | RAPT THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | DCK, MCL1, DTYMK | CHRNB2 4329/4885CHRNA4 4618/4885PIM1 132/4885 |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | DCK, MCL1, DTYMK | CHRNB2 4329/4885CHRNA4 4618/4885PIM1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.